A detailed history of Vanguard Group Inc transactions in Dyne Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 3,440,270 shares of DYN stock, worth $110 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,440,270
Previous 2,329,641 47.67%
Holding current value
$110 Million
Previous $31 Million 215.22%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

BUY
$13.06 - $29.18 $14.5 Million - $32.4 Million
1,110,629 Added 47.67%
3,440,270 $97.7 Million
Q4 2023

Feb 14, 2024

SELL
$6.62 - $13.64 $229,535 - $472,939
-34,673 Reduced 1.47%
2,329,641 $31 Million
Q3 2023

Nov 14, 2023

SELL
$8.6 - $12.18 $210,072 - $297,520
-24,427 Reduced 1.02%
2,364,314 $21.2 Million
Q2 2023

Aug 14, 2023

BUY
$8.53 - $14.28 $8.04 Million - $13.5 Million
941,984 Added 65.11%
2,388,741 $26.9 Million
Q1 2023

May 15, 2023

SELL
$10.88 - $15.0 $2.15 Million - $2.96 Million
-197,653 Reduced 12.02%
1,446,757 $16.7 Million
Q4 2022

Feb 10, 2023

BUY
$9.37 - $13.8 $2.87 Million - $4.22 Million
306,045 Added 22.87%
1,644,410 $19.1 Million
Q3 2022

Nov 14, 2022

BUY
$7.2 - $15.17 $123,408 - $260,013
17,140 Added 1.3%
1,338,365 $17 Million
Q2 2022

Aug 12, 2022

SELL
$4.36 - $10.5 $317,041 - $763,518
-72,716 Reduced 5.22%
1,321,225 $9.08 Million
Q1 2022

May 13, 2022

BUY
$6.52 - $12.27 $7,947 - $14,957
1,219 Added 0.09%
1,393,941 $13.4 Million
Q4 2021

Feb 14, 2022

BUY
$11.89 - $16.07 $1.18 Million - $1.6 Million
99,380 Added 7.68%
1,392,722 $16.6 Million
Q3 2021

Nov 12, 2021

BUY
$15.6 - $21.46 $1.22 Million - $1.68 Million
78,459 Added 6.46%
1,293,342 $21 Million
Q2 2021

Aug 13, 2021

BUY
$15.94 - $22.33 $19.4 Million - $27.1 Million
1,214,883 New
1,214,883 $25.6 Million

Others Institutions Holding DYN

About Dyne Therapeutics, Inc.


  • Ticker DYN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 51,765,400
  • Market Cap $1.65B
  • Description
  • Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...
More about DYN
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.